Rigel Pharmaceuticals, Inc. (RIGL)
32.91
-0.46
(-1.38%)
USD |
NASDAQ |
Jun 18, 16:00
32.90
-0.01
(-0.03%)
Pre-Market: 20:00
Rigel Pharmaceuticals Price to Book Value : 1.521 for June 18, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 18, 2026 | 1.521 |
| June 17, 2026 | 1.542 |
| June 16, 2026 | 1.500 |
| June 15, 2026 | 1.544 |
| June 12, 2026 | 1.518 |
| June 11, 2026 | 1.483 |
| June 10, 2026 | 1.428 |
| June 09, 2026 | 1.420 |
| June 08, 2026 | 1.390 |
| June 05, 2026 | 1.383 |
| June 04, 2026 | 1.398 |
| June 03, 2026 | 1.400 |
| June 02, 2026 | 1.387 |
| June 01, 2026 | 1.38 |
| May 29, 2026 | 1.409 |
| May 28, 2026 | 1.389 |
| May 27, 2026 | 1.362 |
| May 26, 2026 | 1.348 |
| May 22, 2026 | 1.341 |
| May 21, 2026 | 1.349 |
| May 20, 2026 | 1.332 |
| May 19, 2026 | 1.308 |
| May 18, 2026 | 1.322 |
| May 15, 2026 | 1.341 |
| May 14, 2026 | 1.475 |
| Date | Value |
|---|---|
| May 13, 2026 | 1.485 |
| May 12, 2026 | 1.357 |
| May 11, 2026 | 1.211 |
| May 08, 2026 | 1.204 |
| May 07, 2026 | 1.213 |
| May 06, 2026 | 1.233 |
| May 05, 2026 | 1.298 |
| May 04, 2026 | 1.365 |
| May 01, 2026 | 1.359 |
| April 30, 2026 | 1.336 |
| April 29, 2026 | 1.350 |
| April 28, 2026 | 1.412 |
| April 27, 2026 | 1.41 |
| April 24, 2026 | 1.400 |
| April 23, 2026 | 1.420 |
| April 22, 2026 | 1.408 |
| April 21, 2026 | 1.492 |
| April 20, 2026 | 1.502 |
| April 17, 2026 | 1.499 |
| April 16, 2026 | 1.468 |
| April 15, 2026 | 1.482 |
| April 14, 2026 | 1.451 |
| April 13, 2026 | 1.385 |
| April 10, 2026 | 1.350 |
| April 09, 2026 | 1.41 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Pfizer Inc. | 1.595 |
| Madrigal Pharmaceuticals, Inc. | 21.44 |
| CytomX Therapeutics, Inc. | 2.007 |
| ACADIA Pharmaceuticals, Inc. | 2.964 |
| Alnylam Pharmaceuticals, Inc. | 34.51 |
Price to Book Value Related Metrics
| PE Ratio | 1.758 |
| PS Ratio | 2.108 |
| PEG Ratio | 0.0022 |
| Price to Free Cash Flow | 7.971 |
| Price | 32.91 |
| Earnings Yield | 56.89% |
| Market Cap | 608.23M |
| PEGY Ratio | 0.0022 |
| Operating PE Ratio | 5.072 |
| Normalized PE Ratio | 1.758 |